Emerging role of exosomes as biomarkers in cancer treatment and diagnosis.


Journal

Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 07 10 2021
revised: 29 11 2021
accepted: 01 12 2021
pubmed: 7 12 2021
medline: 18 1 2022
entrez: 6 12 2021
Statut: ppublish

Résumé

Cancer is a leading cause of death worldwide and cancer incidence and mortality are rapidly growing. These massive amounts of cancer patients require rapid diagnosis and efficient treatment strategies. However, the currently utilized methods are invasive and cost-effective. Recently, the effective roles of exosomes as promising diagnostic, prognostic, and predictive biomarkers have been revealed. Exosomes are membrane-bound extracellular vesicles containing RNAs, DNAs, and proteins, and are present in a wide array of body fluids. Exosomal cargos have shown the potential to detect various types of cancers at early stages with high sensitivity and specificity. They can also delivery therapeutic agents efficiently. In this article, an overview of recent advances in the research of exosomal biomarkers and their applications in cancer diagnosis and treatment has been provided. Furthermore, the advantages and challenges of exosomes as liquid biopsy targets are discussed and the clinical implications of using exosomal miRNAs have been revealed.

Identifiants

pubmed: 34871719
pii: S1040-8428(21)00352-8
doi: 10.1016/j.critrevonc.2021.103565
pii:
doi:

Substances chimiques

Biomarkers 0
Biomarkers, Tumor 0
MicroRNAs 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

103565

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Niloofar Asadi Hanjani (NA)

Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.

Nazanin Esmaelizad (N)

Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.

Saba Zanganeh (S)

Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.

Abdulwahab Teflischi Gharavi (AT)

Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.

Pegah Heidarizadeh (P)

Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.

Maryam Radfar (M)

Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.

Fateme Omidi (F)

Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.

Ronan MacLoughlin (R)

Research and Development, Science and Emerging Technologies, Aerogen Limited. Galway Business Park, Galway, H91 HE94, Ireland; School of Pharmacy & Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, D02 YN77, Ireland; School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, D02 PN40, Ireland. Electronic address: rmacloughlin@aerogen.com.

Mohammad Doroudian (M)

Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran. Electronic address: mdoroudi@tcd.ie.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH